This clinical trial aims to evaluate different treatments for patients with acute critical illness who require admission to the intensive care unit. The study will test several medications that are commonly used in intensive care, including different types of blood-thinning medications (enoxaparin, dalteparin, nadroparin, and tinzaparin) given by injection under the skin, as well as human albumin solutions given through a vein.
The study uses a platform design, which means it can evaluate multiple treatments at the same time. Patients will receive one or more of the study medications depending on their specific medical needs. The treatments will be given for up to 90 days while patients are in the intensive care unit.
The study will track various outcomes to determine how well the treatments work, including how long patients survive, how many days they spend without needing life support machines, how many days they spend out of the hospital, and their quality of life after treatment. The study will also monitor patients for any side effects from the medications.



Denmark
Finland
Iceland
Sweden
The Netherlands